相关实验视频

Updated: May 7, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

一个随机的Captem或Folfiri的II期试验作为神经内分泌癌症的二线治疗

Alberto Bongiovanni¹, Chiara Liverani², Flavia Foca³

¹Osteoncology and Rare Tumor Center (CDO-TR), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

European journal of cancer (Oxford, England : 1990)

|July 13, 2024

概括

在转移性神经内分泌癌患者中,二线FOLFIRI和CAPTEM化疗显示出可管理的安全性和可比活性. 生物标志物分析确定了与生存结果相关的microRNA.

科学领域:

在瘤学瘤学.
医学瘤学医学瘤学
翻译研究是翻译研究.

背景情况:

神经内分泌癌 (NECs) 预后不好,在以为基础的第一线治疗后没有标准的二线治疗.
在治疗转移性NEC方面,FOLFIRI和CAPTEM疗法初步显示出前景.
这项研究旨在评估这些治疗方案在该患者群体中的有效性和安全性.

研究的目的:

评估FOLFIRI与CAPTEM作为转移性NEC的二线治疗的活性和安全性.
通过下一代测序 (NGS) 的miRNome分析,识别NEC预后的潜在循环生物标志物.

主要方法:

一个开放的,多中心的,随机的II期试验.
患者接受了FOLFIRI或CAPTEM的治疗.
主要终点包括12周疾病控制率 (12w-DCR) 和安全性;次要终点包括整体反应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS).
血清样本经过了NGS miRNome的分析.

主要成果:

这项研究因暂时分析的徒劳而提前停止.
12w-DCR为FOLFIRI的39.1%和CAPTEM的28.0%. 这是一个非常好的结果.
12个月的整体存活率为FOLFIRI的28.4%和CAPTEM的32.4%.
在这两种方案中都观察到可管理的安全概况.
三种微RNA被确定为NEC的独立预测因子,高表达与PFS和OS降低有关.

结论:

在转移性NEC的二线治疗中,FOLFIRI和CAPTEM证明了可管理的安全性和可比的活性.
鉴定的microRNAs可以作为潜在的循环生物标志物,用于预测NEC患者的生存率.

关键词:

这就是Captem Captem的意思.在循环中的miRNA.福尔菲里里 (Folfirifiri) 是一个古老的文化.神经内分泌癌 (NECs) 是一种神经内分泌癌.第二阶段试验试验.

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...